Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Overview

USA - NASDAQ:CGON - US1569441009 - Common Stock

36.48 USD
-0.2 (-0.55%)
Last: 9/25/2025, 5:32:26 PM
36.48 USD
0 (0%)
After Hours: 9/25/2025, 5:32:26 PM

CGON Key Statistics, Chart & Performance

Key Statistics
52 Week High40.47
52 Week Low14.8
Market Cap2.78B
Shares76.25M
Float69.49M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.77
PEN/A
Fwd PEN/A
Earnings (Next)11-10 2025-11-10
IPO01-25 2024-01-25
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CGON short term performance overview.The bars show the price performance of CGON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30 40

CGON long term performance overview.The bars show the price performance of CGON in the last 1, 2 and 3 years. 1 year 2 years 3 years -1 -2 -3

The current stock price of CGON is 36.48 USD. In the past month the price increased by 37.88%. In the past year, price decreased by -3.59%.

CG ONCOLOGY INC / CGON Daily stock chart

CGON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20.64 386.06B
AMGN AMGEN INC 12.43 145.99B
GILD GILEAD SCIENCES INC 14.34 137.72B
VRTX VERTEX PHARMACEUTICALS INC 22.54 97.91B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.93B
REGN REGENERON PHARMACEUTICALS 12.17 58.88B
ARGX ARGENX SE - ADR 76.71 43.52B
ONC BEONE MEDICINES LTD-ADR 5.75 39.08B
INSM INSMED INC N/A 28.66B
BNTX BIONTECH SE-ADR N/A 23.58B
NTRA NATERA INC N/A 22.46B
BIIB BIOGEN INC 8.47 19.89B

About CGON

Company Profile

CGON logo image CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Company Info

CG ONCOLOGY INC

400 Spectrum Center Drive, Suite 2040

Irvine CALIFORNIA US

Employees: 113

CGON Company Website

CGON Investor Relations

Phone: 19492886298

CG ONCOLOGY INC / CGON FAQ

What is the stock price of CG ONCOLOGY INC today?

The current stock price of CGON is 36.48 USD. The price decreased by -0.55% in the last trading session.


What is the ticker symbol for CG ONCOLOGY INC stock?

The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.


On which exchange is CGON stock listed?

CGON stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CG ONCOLOGY INC stock?

17 analysts have analysed CGON and the average price target is 62.02 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 36.48. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CG ONCOLOGY INC worth?

CG ONCOLOGY INC (CGON) has a market capitalization of 2.78B USD. This makes CGON a Mid Cap stock.


How many employees does CG ONCOLOGY INC have?

CG ONCOLOGY INC (CGON) currently has 113 employees.


What are the support and resistance levels for CG ONCOLOGY INC (CGON) stock?

CG ONCOLOGY INC (CGON) has a support level at 27.82 and a resistance level at 36.5. Check the full technical report for a detailed analysis of CGON support and resistance levels.


Is CG ONCOLOGY INC (CGON) expected to grow?

The Revenue of CG ONCOLOGY INC (CGON) is expected to decline by -78.32% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CG ONCOLOGY INC (CGON) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CG ONCOLOGY INC (CGON) stock pay dividends?

CGON does not pay a dividend.


When does CG ONCOLOGY INC (CGON) report earnings?

CG ONCOLOGY INC (CGON) will report earnings on 2025-11-10.


What is the Price/Earnings (PE) ratio of CG ONCOLOGY INC (CGON)?

CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).


What is the Short Interest ratio of CG ONCOLOGY INC (CGON) stock?

The outstanding short interest for CG ONCOLOGY INC (CGON) is 14.73% of its float. Check the ownership tab for more information on the CGON short interest.


CGON Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to CGON. When comparing the yearly performance of all stocks, CGON is one of the better performing stocks in the market, outperforming 80.02% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CGON Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CGON. CGON has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGON Financial Highlights

Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS decreased by -9.62% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.26%
ROE -19.11%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-92.86%
Sales Q2Q%-100%
EPS 1Y (TTM)-9.62%
Revenue 1Y (TTM)-34.72%

CGON Forecast & Estimates

17 analysts have analysed CGON and the average price target is 62.02 USD. This implies a price increase of 70% is expected in the next year compared to the current price of 36.48.

For the next year, analysts expect an EPS growth of -54.58% and a revenue growth -78.32% for CGON


Analysts
Analysts82.35
Price Target62.02 (70.01%)
EPS Next Y-54.58%
Revenue Next Year-78.32%

CGON Ownership

Ownership
Inst Owners104.81%
Ins Owners1.16%
Short Float %14.73%
Short Ratio11.58